{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:22:39Z","timestamp":1773872559441,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03044-z","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T05:14:20Z","timestamp":1731302060000},"page":"523-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of Phosphorodiamidate Morpholino Oligomer Treatment Patterns for Patients with Duchenne Muscular Dystrophy: A MarketScan Claims Analysis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-7093","authenticated-orcid":false,"given":"Alexa C.","family":"Klimchak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-8962","authenticated-orcid":false,"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7274-3942","authenticated-orcid":false,"given":"Bryan","family":"Innis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-7516","authenticated-orcid":false,"given":"Chamindra G.","family":"Laverty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6382-614X","authenticated-orcid":false,"given":"Katherine","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"issue":"1","key":"3044_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77\u201393.","journal-title":"Lancet Neurol"},{"issue":"10","key":"3044_CR2","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","volume":"20","author":"MS Falzarano","year":"2015","unstructured":"Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20(10):18168\u201384.","journal-title":"Molecules"},{"issue":"3","key":"3044_CR3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","volume":"5","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. Compr Physiol. 2015;5(3):1223\u201339.","journal-title":"Compr Physiol"},{"issue":"21","key":"3044_CR4","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJM198805263182104","volume":"318","author":"EP Hoffman","year":"1988","unstructured":"Hoffman EP, Fischbeck KH, Brown RH, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne\u2019s or Becker\u2019s muscular dystrophy. N Engl J Med. 1988;318(21):1363\u20138.","journal-title":"N Engl J Med"},{"issue":"7","key":"3044_CR5","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/genes13071241","volume":"13","author":"G Eser","year":"2022","unstructured":"Eser G, Topalo\u011flu H. Current outline of exon skipping trials in Duchenne muscular dystrophy. Genes (Basel). 2022;13(7):1241.","journal-title":"Genes (Basel)."},{"issue":"5","key":"3044_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637\u201347.","journal-title":"Ann Neurol"},{"issue":"3","key":"3044_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3233\/JND-230107","volume":"11","author":"S Nicolau","year":"2024","unstructured":"Nicolau S, Malhotra J, Kaler M, et al. Increase in full-length dystrophin by exon skipping in Duchenne muscular dystrophy patients with single exon duplications: an open-label study. J Neuromuscul Dis. 2024;11(3):679\u201385.","journal-title":"J Neuromuscul Dis"},{"key":"3044_CR8","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.nmd.2022.07.248","volume":"32","author":"S Iannaccone","year":"2022","unstructured":"Iannaccone S, Phan H, Straub V, et al. P.132 Casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: interim results from the Phase 3 ESSENCE trial. Neuromusc Disord. 2022;32:S102.","journal-title":"Neuromusc Disord"},{"issue":"1","key":"3044_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais L, Mercuri E, Straub V, et al. Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial. Nucleic Acid Ther. 2022;32(1):29\u201339.","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"3044_CR10","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/jcm10040820","volume":"10","author":"F Fortunato","year":"2021","unstructured":"Fortunato F, Rossi R, Falzarano MS, Ferlini A. Innovative therapeutic approaches for Duchenne muscular dystrophy. J Clin Med. 2021;10(4):820.","journal-title":"J Clin Med"},{"key":"3044_CR11","unstructured":"EXONDYS 51 (eteplirsen) injection [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc; 2020."},{"key":"3044_CR12","unstructured":"VYONDYS 53 (golodirsen) injection [package insert]. Sarepta, MA: Sarepta Therapeutics, Inc; 2019."},{"key":"3044_CR13","unstructured":"VILTEPSO (viltolarsen) injection [package insert]. Paramus, NJ: NS Pharma, Inc; 2020."},{"key":"3044_CR14","unstructured":"AMONDYS 45 (casimersen) injection [package insert]. Sarepta, MA: Sarepta Therapeutics, Inc; 2021."},{"key":"3044_CR15","unstructured":"Sabat\u00e9 E. Adherence to long-term therapies. Evidence for action. Switzerland. World Health Organization. 2003. https:\/\/iris.who.int\/bitstream\/handle\/10665\/42682\/9?sequence=1. Accessed 1 Jul 2024."},{"key":"3044_CR16","doi-asserted-by":"publisher","unstructured":"Khan R, Socha-Dietrich K. Investing in medication adherence improves health outcomes and health system efficiency. Paris. OECD Health Working Papers, No. 105. 2018. https:\/\/doi.org\/10.1787\/8178962c-en. Accessed 1 Jul 2024.","DOI":"10.1787\/8178962c-en"},{"issue":"1","key":"3044_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016982","volume":"8","author":"RL Cutler","year":"2018","unstructured":"Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1): e016982.","journal-title":"BMJ Open"},{"issue":"3","key":"3044_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/dom.14603","volume":"24","author":"M Evans","year":"2022","unstructured":"Evans M, Engberg S, Faurby M, Fernandes J, Hudson P, Polonsky W. Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: a systematic literature review. Diabetes Obes Metab. 2022;24(3):377\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3044_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019;9(4): e027049.","journal-title":"BMJ Open"},{"issue":"4","key":"3044_CR20","first-page":"495","volume":"44","author":"S Khan","year":"2019","unstructured":"Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495\u2013507.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"3044_CR21","first-page":"1349","volume":"25","author":"MB Glassberg","year":"2019","unstructured":"Glassberg MB, Trygstad T, Wei D, Robinson T, Farley JF. Accuracy of prescription claims data in identifying truly nonadherent patients. J Manag Care Spec Pharm. 2019;25(12):1349\u201356.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"3044_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/0018578720918550","volume":"56","author":"RS Rasu","year":"2021","unstructured":"Rasu RS, Hunt SL, Dai J, Cui H, Phadnis MA, Jain N. Accurate medication adherence measurement using administrative data for frequently hospitalized patients. Hosp Pharm. 2021;56(5):451\u201361.","journal-title":"Hosp Pharm"},{"key":"3044_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ahj.2022.10.083","volume":"256","author":"N Haff","year":"2023","unstructured":"Haff N, Choudhry NK, Isaac T, et al. Disagreement between pharmacy claims and direct interview to identify patients with non-adherence to chronic cardiometabolic medications. Am Heart J. 2023;256:51\u20139.","journal-title":"Am Heart J"},{"key":"3044_CR24","unstructured":"Merative\u2122. Merative\u2122 MarketScan\u00ae Research. Commercial Claims and Encounters (CCAE) and Multi-State Medicaid databases. https:\/\/www.merative.com\/documents\/brief\/marketscan-explainer-general. Accessed 1 July 2024."},{"issue":"1","key":"3044_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","volume":"10","author":"AM Peterson","year":"2007","unstructured":"Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3\u201312.","journal-title":"Value Health"},{"issue":"1","key":"3044_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40545-021-00385-w","volume":"14","author":"D Prieto-Merino","year":"2021","unstructured":"Prieto-Merino D, Mulick A, Armstrong C, et al. Estimating proportion of days covered (PDC) using real-world online medicine suppliers\u2019 datasets. J Pharm Policy Pract. 2021;14(1):113.","journal-title":"J Pharm Policy Pract"},{"issue":"1","key":"3044_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.53094","volume":"7","author":"D Hong","year":"2024","unstructured":"Hong D, Avorn J, Wyss R, Kesselheim AS. Characteristics of patients receiving novel muscular dystrophy drugs in trials vs routine care. JAMA Netw Open. 2024;7(1): e2353094.","journal-title":"JAMA Netw Open"},{"key":"3044_CR28","unstructured":"Grabich S, Waldrop MA, Santra S, et al. Interim analysis of EVOLVE: evaluating eteplirsen treatment in nonambulatory patients in routine clinical practice from a phase 4 observational study. In: Poster presentation (M180) at the 2024 Muscular Dystrophy Association (MDA) clinical & scientific conference. Orlando, FL, USA; 2024."},{"key":"3044_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mus.28075","volume":"70","author":"J Iff","year":"2024","unstructured":"Iff J, Done N, Tuttle E, et al. Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls. Muscle Nerve. 2024;70:60\u201370.","journal-title":"Muscle Nerve"},{"issue":"7","key":"3044_CR30","first-page":"756","volume":"20","author":"EJ Campagna","year":"2014","unstructured":"Campagna EJ, Muser E, Parks J, Morrato EH. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication. J Manag Care Pharm. 2014;20(7):756\u201366.","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"3044_CR31","first-page":"90","volume":"29","author":"C Xu","year":"2023","unstructured":"Xu C, Ferrante SA, Fitzgerald T, Pericone CD, Wu B. Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals. J Manag Care Spec Pharm. 2023;29(1):90\u2013100.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"3044_CR32","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/ajhp\/zxab392","volume":"79","author":"J Loucks","year":"2021","unstructured":"Loucks J, Zuckerman AD, Berni A, Saulles A, Thomas G, Alonzo A. Proportion of days covered as a measure of medication adherence. Am J Health Syst Pharm. 2021;79(6):492\u20136.","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"3044_CR33","first-page":"1073","volume":"25","author":"SL Canfield","year":"2019","unstructured":"Canfield SL, Zuckerman A, Anguiano RH, et al. Navigating the wild west of medication adherence reporting in specialty pharmacy. J Manag Care Spec Pharm. 2019;25(10):1073\u20137.","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"3044_CR34","first-page":"1282","volume":"25","author":"D Paolella","year":"2019","unstructured":"Paolella D, Cherry E, Jolly JA, DeClercq J, Choi L, Zuckerman A. Closing the gap: identifying rates and reasons for nonadherence in a specialty population. J Manag Care Spec Pharm. 2019;25(11):1282\u20138.","journal-title":"J Manag Care Spec Pharm"},{"key":"3044_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s11657-013-0128-1","volume":"8","author":"AM Burden","year":"2013","unstructured":"Burden AM, Huang A, Tadrous M, Cadarette SM. Variation in the days supply field for osteoporosis medications in Ontario. Arch Osteoporos. 2013;8:128.","journal-title":"Arch Osteoporos"},{"issue":"4","key":"3044_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.semradonc.2019.05.009","volume":"29","author":"YT Shih","year":"2019","unstructured":"Shih YT, Liu L. Use of claims data for cost and cost-effectiveness research. Semin Radiat Oncol. 2019;29(4):348\u201353.","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"3044_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/1062860606288774","volume":"21","author":"PT Tyree","year":"2006","unstructured":"Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance claims data for utilization analysis. Am J Med Qual. 2006;21(4):269\u201375.","journal-title":"Am J Med Qual"},{"issue":"1","key":"3044_CR38","first-page":"99","volume":"30","author":"I Hernandez","year":"2024","unstructured":"Hernandez I, Hung A. A primer on brand-name prescription drug reimbursement in the United States. J Manag Care Spec Pharm. 2024;30(1):99\u2013106.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"3044_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1377\/hlthaff.2017.1325","volume":"37","author":"JD Gottlieb","year":"2018","unstructured":"Gottlieb JD, Shapiro AH, Dunn A. The complexity of billing and paying for physician care. Health Aff. 2018;37(4):619\u201326.","journal-title":"Health Aff"},{"key":"3044_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhealeco.2017.07.001","volume":"55","author":"J Clemens","year":"2017","unstructured":"Clemens J, Gottlieb JD, Moln\u00e1r TL. Do health insurers innovate? Evidence from the anatomy of physician payments. J Health Econ. 2017;55:153\u201367.","journal-title":"J Health Econ"},{"issue":"9","key":"3044_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.32643","volume":"6","author":"YT Shih","year":"2023","unstructured":"Shih YT, Xu Y, Yao JC. Financial outcomes of \u201cbagging\u201d oncology drugs among privately insured patients with cancer. JAMA Netw Open. 2023;6(9): e2332643.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"3044_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/pharmacy11040111","volume":"11","author":"H Jusufi","year":"2023","unstructured":"Jusufi H, Boivin N. Navigating access and optimizing medication infusions in an academic medical center: a quality improvement study. Pharmacy (Basel). 2023;11(4):111.","journal-title":"Pharmacy (Basel)."},{"issue":"11","key":"3044_CR43","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/acr.24062","volume":"72","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Harkness T, Fu X, Stone JH, Choi HK, Walensky RP. Treatment delays associated with prior authorization for infusible medications: a cohort study. Arthritis Care Res (Hoboken). 2020;72(11):1543\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"3044_CR44","first-page":"354","volume":"11","author":"M Tompkinson","year":"2020","unstructured":"Tompkinson M, Fine K, Gruber D, Abraham I, McBride A. Perceptions of health-care workers of the cost and safety of oral oncolytic agents for patients: a survey. J Adv Pract Oncol. 2020;11(4):354\u201365.","journal-title":"J Adv Pract Oncol"},{"key":"3044_CR45","unstructured":"Turner AM, G. Clark, S. Impacts of prior authorization on health care costs and quality. The National Institute for Health Care Reform (NIHCR). 2019. https:\/\/www.nihcr.org\/analysis\/impacts-of-prior-authorization-on-health-care-costs-and-quality\/. Accessed 1 July 2024."},{"key":"3044_CR46","unstructured":"UnitedHealthcare. Individual exchange medical benefit drug policy: Viltepso\u00ae (Viltolarsen). Effective 1 June 2024. https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/policies\/comm-medical-drug\/viltepso.pdf. Accessed 1 July 2024."},{"key":"3044_CR47","unstructured":"UnitedHealthcare. Individual exchange medical benefit drug policy: Amondys 45\u00ae (Casimersen). Effective 1 May, 2024. https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/policies\/comm-medical-drug\/amondys.pdf. Accessed 1 July 2024."},{"key":"3044_CR48","unstructured":"UnitedHealthcare. Individual exchange medical benefit drug policy: Exondys 51\u00ae (Eteplirsen). Effective 1 May, 2024. https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/policies\/comm-medical-drug\/exondys-51-eteplirsen.pdf. Accessed 1 July 2024."},{"key":"3044_CR49","unstructured":"UnitedHealthcare. Individual exchange medical benefit drug policy: Vyondys 53\u00ae (Golodirsen). Effective 1 May, 2024. https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/policies\/comm-medical-drug\/vyondys-53.pdf. Accessed 1 July 2024."},{"key":"3044_CR50","unstructured":"Cigna. Drug and biologic coverage policy: viltolarsen. Effective 15 January 2024. https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/pharmacy\/ip_0066_coveragepositioncriteria_viltolarsen.pdf. Accessed 1 July 2024."},{"key":"3044_CR51","unstructured":"Cigna. Drug and biologic coverage policy: eteplirsen. Effective 1 September 2023. https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/pharmacy\/ip_0135_coveragepositioncriteria_eteplirsen.pdf. Accessed 1 July 2024."},{"key":"3044_CR52","unstructured":"Cigna. Drug and biologic coverage policy: Golodirsen. Effective 1 June 2023. https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/pharmacy\/ip_0136_coveragepositioncriteria_golodirsen.pdf. Accessed 1 July 2024."},{"key":"3044_CR53","unstructured":"Cigna. drug and biologic coverage policy: Casimersen. Effective 1 July 2023. https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/pharmacy\/ip_0137_coveragepositioncriteria_casimersen.pdf. Accessed 1 July 2024."},{"key":"3044_CR54","unstructured":"Kaiser Foundation Health Plan of the Northwest. Clinical Oversight Review Board (CORB) criteria for prescribing: Eteplirsen (Exondys 51). Effective 1 June 2023. https:\/\/healthy.kaiserpermanente.org\/content\/dam\/kporg\/final\/documents\/formularies\/nw\/kp-exondys-51-nw-en.pdf. Accessed 1 July 2024."},{"key":"3044_CR55","unstructured":"Kaiser Foundation Health Plan of the Northwest. Clinical Oversight Review Board (CORB) criteria for prescribing: Golodirsen (Vyondys 53). Effective 1 June 2023. https:\/\/healthy.kaiserpermanente.org\/content\/dam\/kporg\/final\/documents\/formularies\/nw\/kp-vyondys-53-nw-en.pdf. Accessed 1 July 2024."},{"key":"3044_CR56","unstructured":"Kaiser Foundation Health Plan of the Northwest. Clinical Oversight Review Board (CORB) criteria for prescribing: Casimersen (Amondys 45). Effective 1 June 2023. https:\/\/healthy.kaiserpermanente.org\/content\/dam\/kporg\/final\/documents\/formularies\/nw\/kp-amondys-45-nw-en.pdf. Accessed 1 July 2024."},{"key":"3044_CR57","unstructured":"Kaiser Foundation Health Plan of the Northwest. Clinical Oversight Review Board (CORB) criteria for prescribing: Viltolarsen (Viltepso). Effective 1 June 2023. https:\/\/espanol.kaiserpermanente.org\/content\/dam\/kporg\/final\/documents\/formularies\/nw\/kp-viltepso-nw-en.pdf. Accessed 1 July 2024."},{"key":"3044_CR58","unstructured":"Blue Cross Blue Shield of Massachusetts. Pharmacy medical policy: antisense oligonucleotide medications. Last Updated July 2021. https:\/\/www.bluecrossma.org\/medical-policies\/sites\/g\/files\/csphws2091\/files\/acquiadam_assets\/2021-09\/027%20Antisense%20Oligonucleotide%20Medications%20prn.pdf. Accessed 12 April 2024."},{"issue":"1","key":"3044_CR59","first-page":"13","volume":"116","author":"V Rao","year":"2024","unstructured":"Rao V, Dharia I, Gibilisco J, et al. Delay in prior authorization of biologic therapy: another possible cause of healthcare disparity in IBD patients. J Natl Med Assoc. 2024;116(1):13\u20135.","journal-title":"J Natl Med Assoc"},{"key":"3044_CR60","unstructured":"Centers for Disease Control and Prevention: MD STARnet data and statistics\u2014insurance type. https:\/\/www.cdc.gov\/ncbddd\/musculardystrophy\/data.html. Accessed 8 May 2024."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03044-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03044-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03044-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:03:14Z","timestamp":1738234994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03044-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3044"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03044-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"James Signorovitch is an employee of Analysis Group, Inc., which has received consulting fees from Sarepta Therapeutics, Inc. Alexa C. Klimchak, Bryan Innis, and Katherine Gooch are employees of Sarepta Therapeutics, Inc., and may own stock\/options in the company. Chamindra G Laverty declares contracts (as principal investigator) from Sarepta Therapeutics, Dyne Therapeutics, Avidity Biosciences, FibroGen, Scholar Rock, Novartis Gene Therapies, and Biohaven; consulting fees from Sarepta Therapeutics (payments to her institution), NS Pharma (payments to herself), and Avidity (payments to her institution), Catalyst (payments to herself), SolidBio (payments to herself), Novartis (payments to herself), Biogen (payments to herself); and support for attending meetings and\/or travel from the Muscular Dystrophy Association, CureCMD, and CureSMA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"MarketScan\u00ae data included in this study were provided by and used with permission from Merative\u2122. Institutional review board approval was not required to conduct this study, as data were de-identified and compliant with Health Insurance Portability and Accountability Act (HIPAA) regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}